摩根士丹利发表研究报告指,药明系公司当前的估值未能充分反映早期需求复苏、价格见底以及新兴疗法带来的上行潜力等正面因素,认为业绩向好和积压订单增长均是行业正在回升的明确迹象,历时长达一年的《生物安全法案》事件去年底起宣告尘埃落定,而CRO及CDMO板块估值已回升至与2024年初水平,经历持续一年的低迷,认为随着全球生物科技行业融资逐渐回暖,研发需求复苏,加上产能利用率提升及ADC、BsAbs等新兴...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
No relevant data is available
If the download button clicks without skipping, click on the top right menu and select "Open in Browser."